ai3Bio
ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.
$48MSeries A
LeadZC
Ziff Capital Partners
Activity from announced rounds
All recorded activity
Ziff Capital Partners is the firm named in Stellular and ai3Bio coverage, with ai3Bio identifying it as founding investor and co-lead.
Recorded funding activity
Stellular develops biologics for ocular disease. Ai3Bio develops therapies targeting Th17 immune cells. The pending relationship stays in draft while the firm’s event-specific roles are preserved.
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $48M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in all activityStellular Bio
Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases
UndisclosedSeries A
Role not disclosed